Benjamin Burnett
Stock Analyst at Wells Fargo
(2.17)
# 2,861
Out of 4,974 analysts
73
Total ratings
48.08%
Success rate
-5.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Assumes: Overweight | $163 | $125.17 | +30.22% | 1 | Sep 3, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $31 | $15.73 | +97.08% | 1 | Sep 3, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Equal-Weight | $16 | $15.76 | +1.52% | 1 | Sep 3, 2025 | |
| ALKS Alkermes | Initiates: Overweight | $44 | $29.94 | +46.96% | 1 | Sep 3, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.01 | +197.03% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $54.86 | -10.68% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $72.63 | +67.97% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $20.88 | +230.46% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $27.16 | +150.37% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.15 | +300.00% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $12.74 | +351.33% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $5.07 | +15,284.62% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $48 | $39.18 | +22.51% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $40.50 | +58.02% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $60.72 | +54.82% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $1.69 | +136.69% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.36 | +129.36% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.49 | +904.02% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $40.18 | +795.97% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.55 | +2,823.98% | 1 | Jan 6, 2021 |
Axsome Therapeutics
Sep 3, 2025
Assumes: Overweight
Price Target: $163
Current: $125.17
Upside: +30.22%
Centessa Pharmaceuticals
Sep 3, 2025
Initiates: Overweight
Price Target: $31
Current: $15.73
Upside: +97.08%
Avadel Pharmaceuticals
Sep 3, 2025
Initiates: Equal-Weight
Price Target: $16
Current: $15.76
Upside: +1.52%
Alkermes
Sep 3, 2025
Initiates: Overweight
Price Target: $44
Current: $29.94
Upside: +46.96%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.01
Upside: +197.03%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $54.86
Upside: -10.68%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $72.63
Upside: +67.97%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $20.88
Upside: +230.46%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $27.16
Upside: +150.37%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.15
Upside: +300.00%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $12.74
Upside: +351.33%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $5.07
Upside: +15,284.62%
Sep 3, 2025
Assumes: Overweight
Price Target: $48
Current: $39.18
Upside: +22.51%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $40.50
Upside: +58.02%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $60.72
Upside: +54.82%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $1.69
Upside: +136.69%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.36
Upside: +129.36%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.49
Upside: +904.02%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $40.18
Upside: +795.97%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.55
Upside: +2,823.98%